Pimecrolimus Suppliers & Bulk Manufacturers
Available Forms: Creams
Available Strengths: 1%
Reference Brands: Elidel (USA/EU)
Category:
Derma Drugs
Pimecrolimus is available in Creams
and strengths such as 1%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pimecrolimus is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pimecrolimus can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pimecrolimus is a topical immunosuppressant drug belonging to the calcineurin inhibitor class, primarily used in the treatment of atopic dermatitis (eczema). It works by selectively inhibiting calcineurin, which reduces T-cell activation and the release of inflammatory cytokines in the skin, thereby controlling inflammation, redness, and itching. Pimecrolimus is formulated as a topical cream, allowing localized action with minimal systemic absorption, making it suitable for sensitive skin areas such as the face and neck.
Originally developed and marketed by Novartis under the trade name Elidel, pimecrolimus has been shown to be effective not only for eczema but also for a variety of inflammatory skin conditions, including seborrheic dermatitis, cutaneous lupus erythematosus, oral lichen planus, vitiligo, and psoriasis. Its mechanism and clinical profile are similar to tacrolimus, another calcineurin inhibitor, providing an alternative non-steroidal option for long-term management of inflammatory dermatologic disorders.
Pimecrolimus offers a targeted immunomodulatory effect, making it an important therapeutic option for patients requiring long-term control of chronic skin inflammation while avoiding the adverse effects associated with prolonged corticosteroid use.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing